
    
      This is a Phase 2, randomized (The study medication is assigned by chance.), 5-arm, open
      label (All people know the identity of the intervention.), multicentre (study conducted at
      multiple sites) study. Approximately, 84 participants will be randomized to 5 different arms
      in a 2:2:1:1:1 ratio. In treatment arms 1 and 2, participants will receive 12 weeks of triple
      therapy (use of 3 medications) with TMC435 50 or 100 mg once daily plus Peginterferon Alfa-2a
      and Ribavirin followed by 12 weeks of treatment with Peginterferon Alfa-2a and Ribavirin. In
      treatment arms 3 and 4, participants will receive 24 weeks of triple therapy with TMC435 50
      or 100 mg once daily plus Peginterferon Alfa-2a and Ribavirin. In treatment arm 5 (control
      group), participants will receive Peginterferon Alfa-2a and Ribavirin for 48 weeks. This
      study will consist a screening phase of upto 6 weeks, treatment phase of upto 48 weeks and a
      post treatment follow-up period of 24 weeks. Safety evaluations will include assessment of
      adverse events, clinical laboratory tests, vital signs, and cardiovascular safety.
    
  